$16.48 (8.99%)

Volume: 580.623k

Closed: Dec 02, 2022

Hollow Logo Score: 0.715

FibroGen Stock Forecast

$16.48 (8.99%)

Volume: 580.623k

Closed: Dec 02, 2022

Score Hollow Logo 0.715

FibroGen Company Profile

409 Illinois Street

San Francisco CA 94158

415 978 1200

www.fibrogen.com

Industry: Biotechnology

Sector: Healthcare

FibroGen

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT